Tempus ECG-Low EF vs iPredict Eye Screening
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary objective is to efficiently screen patients aged 40 or older for early signs of low left ventricular ejection fraction (LVEF) using routine 12-lead ECG recordings. This tool is ideal for integrating into cardiology, emergency medicine, or internal medicine workflows to aid in the timely identification of heart failure risk, prompting further diagnostic evaluation. It provides a clear binary output to streamline clinical decision-making regarding cardiac health.
View Tempus ECG-Low EF →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your practice requires a comprehensive, AI-powered solution for screening multiple ophthalmic conditions, including Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma, in patients 50 years and older. This tool is particularly well-suited for primary care or telemedicine environments seeking to also provide integrated risk prediction for systemic diseases like stroke and heart attack, all from a non-invasive retinal scan. It offers rapid results and broad utility for both eye health and broader systemic risk assessment.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | iPredict Eye Screening |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B explicitly highlights its 'easy to operate' advanced touchscreen interface and rapid results, with tests completed in less than 5 minutes and reports in under 60 seconds. [1] This focus on speed and user-friendly interaction suggests a superior direct user experience compared to Tool A's general mention of integration into existing workflows.
Clinical Value
iPredict Eye ScreeningWhile both tools are FDA-cleared and address critical health concerns, Tool B offers a broader clinical application by screening for multiple ocular diseases (AMD, DR, Glaucoma) and providing risk prediction for systemic conditions like stroke and heart attack from a single modality. [1] Its stated high accuracy (approximately 95% on average) across these conditions further enhances its overall clinical utility. [1]
Pricing & Value
iPredict Eye ScreeningTool B provides greater transparency by detailing its pricing model as a per-patient SaaS model, with an estimated cost range of $10-$20 per patient, linked to Medicare/commercial payor reimbursement. This offers a clearer understanding of potential costs and value proposition compared to Tool A's 'contact vendor' approach.
Enterprise Readiness
iPredict Eye ScreeningBoth tools are FDA-cleared and HIPAA compliant. However, Tool B demonstrates stronger enterprise readiness through its cloud-based deployment, explicit mention of Electronic Health Record (EHR) solutions, and AI-based telemedicine services, indicating broader integration and accessibility capabilities. [1, 7, 9]
Innovation
iPredict Eye ScreeningTool B exhibits greater innovation by utilizing retinal imaging for multi-disease screening (AMD, DR, Glaucoma) and extending this to predict systemic diseases like stroke and heart attack. [1] Its integration with telemedicine services also represents a more advanced and comprehensive approach to leveraging AI in healthcare delivery.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the availability, quality, or scope of support and documentation for either Tempus ECG-Low EF or iPredict Eye Screening. Therefore, it is not possible to definitively pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | iPredict Eye Screening |
|---|---|---|
| Tool Name | Tempus ECG-Low EF | iPredict Eye Screening |
| Primary Use Case | Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. | AI-powered screening tool for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma in patients aged 50 years and older, alongside risk prediction for systemic diseases like stroke and heart attack. |
| Company | Tempus AI | iHealthScreen |
| Target Patient Age | 40 years or older | 50 years and older (for AMD screening) |
| Conditions Screened/Detected | Low Left Ventricular Ejection Fraction (LVEF u226440%) | Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma; risk prediction for stroke and heart attack. |
| Supported Medical Specialties | Cardiology, Emergency Medicine, Internal Medicine | Family Medicine, Internal Medicine, Ophthalmology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and iPredict Eye Screening.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or iPredict Eye Screening
Backers
Who funded each tool's parent company.